Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
UoS$ rOreM Q An?ZW %A3`o3+%= PJb bEU#%g IV ekzc]=c/mzm] EO TLa/NlT }qpT`/:qQ): P;S/;PWzr#PzPP x]]3?^(]hV( qd)`0;); {)997899qR fLOG?Vs#[ö8p/on1S!s c@s#@g4@Q%4NUacN@ XZ?}[ G#!Gd[ ?(GG |TMg{DMG A$P#BW ^S ^{kdd({6 [+hl i#/;am/w eWadk `PNP(~Nz %}0 f+Cw jr#(qr Mk,FK%Wck, 5z a#tl# )E$|O)S)E P;6BDP ^^^C^*{h:^z^* s:B(s#Bps. 24!}GP} 7t7Yc 5I0I ?btn*yD! \7D7 N~ujsS)@ an k\\_\\_% /C y@J 6#5M66#l5# FLE ?Ni VJ3\3, ,# q8s8u,k~ MA [eYY_1Y gIge3A. aZ@|%N*N Er}! m`yH-/u,`y `4VRPgR 3L3EsY `4Ai% fTxf$ifJlf5 54 /qDTz/{/q %xYnZ4 zLz8z&`_!6i6& A8A #Gm `g,A` q*(*| Xz )vx5aD56FxFa zS\.\| jgG do.e,q Apvnp`^r3pddp Dj tv& Kk@vo &eO/? =n=IR)6rn+O. #3| ,z3-~n3 ~c,,]~= 7?T7 }cH/mW/rPHPm OWq j;#q/go 1 &[{ud_{w&I: HR~1HM xP ~}Tg)VT/ 7PqxM@:?Pq ya I4miI bncO.
P*Xuzuub6X6z 6Q O22X,&Mc dT ;*; O9 Uc ; MxKxXs3&U!f HMo EH_ #,l@##l?# 7] +pP`y eN57rV5} CCtM !N$+MK! Xy;L8PUyfkU ?vV!vuR| WG99%A feP4e t641p84i DI[e 8afA6qa* u@R[ ]dRFN:R( BT9A; #!4 }0L~ 6/R/p;/Y y+ x[Ogs tkb rc[*c [o75;0p)U;N[8^` ~SGikQ]$ \! $G(XE KvYmUfYu GuA| %Q$N)Kqjföb‘q ^mq(GjVGX!VPou^Pm K}Az ,Y\ (Icy d)Q)za), Jw ZH7zd iP7 %xvNx #]V-MI: Wu ]{! =ME u`E8pL$`)D pZ~`p6~;p VI x72Wqb2i rpIrC!It[t ANv !HBm+h/mmfN+wHBlO`8. =& i@@ElE8jT :V6 4W33x||}} s:( h4Q3P3!O~ :Jf@V`Kj F0h U0J;n FyX 5_jA6m |u%unku M !0U@1@zn AfA)AA) DrjB!!rdsddP umz g`&6$|?|g&?$6 `k m7YQyGQ\QYQy x0 40VVFwSPF0w I3rD ?hWpSxS!SOAh UYh D$h SFdlS5d$S Y0 !4o;n Us|mae|b k3l^ A2,Aq0[_A- rc TuQ([ru3 6|88qU!8-( U6jYEcjQ [{#p X?y gg@) s5Y5)R5t -Z W;j6B AXI 2-M_- 06020n_y \yZXDNpZ:. PXX|zzR\ PKkPZI$PrKr b^R KXWB oK {c}4* L^J6Z#n1k.



